The engagers targeting CD16 have been chosen in the first generation to trigger NK cell cytotoxicity [181], cooperated with the recognition of different epitopes of tumor cell surface including CD33 or CD33/CD123 on AML cells [182, 183], CD33 on MDS cells [184], CD30 on HL cells [185, 186], CD19/CD20 or HLA-II on B cell lymphomas cells [187, 188]. This evidence concerns the gene CD33 and acute myeloid leukemia.